“…If the infection/disease of interest is relatively rare, it is easy to see that this testing strategy can confer a substantial reduction in testing cost, that is, in such settings a majority of the pools will be negative allowing practitioners to diagnose all contributing individuals at the expense of a single diagnostic test per pool. Given these potential cost savings, group testing has been adopted to screen for a variety of infectious diseases (eg, HIV, 2 Zika, 3 influenza, 4 SARS‐CoV‐2 5 ) as well as in alternate application areas (eg, animal testing, 6 , 7 bio‐terrorism detection, 8 drug discovery, 9 genetics 10 ).…”